Adaptive Approaches in Clinical Drug Development

The crisis in the overall productivity of pharmaceutical research and development (R&D) has attracted attention to innovative ways to improve drug development. This article describes such an initiative that resulted in the creation of a unique cross-functional group of experienced drug developers with backgrounds in clinical pharmacology, medicine and statistics. The objective of the initiative was to test whether a small task force would be able to dramatically improve clinical development planning on a strategic level by (i) ‘walking the talk’ of the ‘learn and confirm’ philosophy, through hands-on interactions with project teams across multiple therapeutic areas; (ii) enabling real-time learning in clinical drug development, through a culture open to innovative and adaptive approaches in the design, implementation and execution of clinical trials; (iii) serving as an integrator across functions and stakeholders, from discovery to commercial; and (iv) ensuring consistent quality in development planning, across much of the R&D portfolio. This adaptive approach has become a platform to integrate cross-functional expertise and to increase the information value per resource unit invested during drug development, through rigorous application of simulation guided planning of development strategies and clinical trials. We also describe opportunities and challenges to successfully designing and conducting adaptive trials in a pharmaceutical R&D environment, in light of recent regulatory developments and guidelines.

[1]  Jeff Maca,et al.  Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples , 2006 .

[2]  Paul Gallo,et al.  Sample Size Reestimation: A Review and Recommendations , 2006 .

[3]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[4]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[5]  D. V. Lindley,et al.  Prospects for the Future The Next 50 Years , 1984 .

[6]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[7]  M. Krams,et al.  Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.

[8]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[9]  Donald A. Berry,et al.  Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .

[10]  Michael Krams,et al.  Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .

[11]  L. Haines,et al.  Bayesian Optimal Designs for Phase I Clinical Trials , 2003, Biometrics.

[12]  V. Fedorov,et al.  Adaptive designs for dose-finding based on efficacy–toxicity response , 2006 .

[13]  Vladimir Dragalin,et al.  Adaptive Designs: Terminology and Classification , 2006 .

[14]  Paul Gallo,et al.  Adaptive Dose-Response Studies , 2006 .

[15]  Andrew P Grieve,et al.  ASTIN: a Bayesian adaptive dose–response trial in acute stroke , 2005, Clinical trials.